In vivo measurements of lung dose

Drug Delivery to the Lung

Volumn , Issue , 2001, Pages 173-209

  Everard, Mark L ^a   Dolovich, Myrna B ^b  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944042354     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (135)

1. Pedersen S. Inhalers and nebulisers: which to choose and why? Respir Med 1996; 90:69–77.
2. Everard ML. Assessment of aerosol delivery systems. Pediatr Pulmonol 1997; 16:186–187.
3. Dolovich M. Aerosol delivery to children: what to use, how to choose. Pediatr Pulmonol 1999; 18 (suppl):79–82.
4. Sakula A. A history of asthma. J R Coll Phys Lond 1988; 22:36–44.
5. Webb J, Rees J, Clark TJ. A comparison of the effects of different methods of administration of beta 2 sympathomimetics in patients with asthma. Br J Dis Chest 1982; 76:351–357.
6. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994; 7:49–75.
7. Wolff RK. Safety of inhaled proteins for thrapeutic use. J Aerosol Med 1998; 11:197–219.
8. Laube BL. Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with non-insulin dependent diabetes mellitus. J Aerosol Med 1998; 11:153–173.
9. Farr SJ, Gonda I, Licko V. Physicochemical and physiological factors influencing the effectiveness of inhaled insulin. In: Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, 1988:25–33.
10. Virgolini I, Kurtaran A, Leimer M, Smith-Jones P, Agis II, Angelberger P, Kletter K, Valent P, Linkesch W, Eichler H-G. Inhalation scintigraphy with iodine 123-labeled interferon gamma-1 b: Pulmonary deposition and dose escalation study in healthy volunteers. J Nucl Med 1997; 38:1475–1481.
11. Dolovich M. Measurement of particle size characteristics of metered dose inhaler (MDI) aerosols. J Aerosol Med 1991; 4:251–253.
12. Dolovich M. In vitro measurement of medications from MDIs and spacers devices. J Aerosol Med 1996; 9(supp 1):S49–S58.
13. Clark AR. The use of laser diffraction for evaluation of the aerosol clouds generated by medical nebulizers. Int J Pharm 1994.
14. Thiel C. Can in vitro particle size measurements be used to predict pulmonary deposition of aerosol from inhalers? J Aerosol Med 1998; 11(suppl 1):S43–S52.
15. Clark AD, Gonda I, Newhouse MT. Towards meaningful laboratory tests for evaluation of pharmaceutical aerosols. J Aerosol Sci 1998; 11(suppl 1): S1–S7.
16. Newman SP. J Aerosol Med 1998; 11: S97–S104.
17. Egan M, Clark AR. Modelling the deposition of inhaled powdered drug aerosols. J Aerosl Sci 1994; 25: 175–86
18. Burnell P, Malton A, Reavill K, Ball M. Design, validation and initial testing of the electronic lung. J Aerosol Sci 1998; 29:1011–1025.
19. Stahlhofen W, Gebhart J, Heyder J. Experimental determination of regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J 1980; 41: 38–98.
20. Schulz A, Tuch T, Brand P. Schulz H, Mutius E, Erdl R, Reinhardt D, Heyder J. Aerosol bolus dispersion during breathing in healthy children. J Aerosol Med 1993; 6 (suppl): 65–69.
21. Blanchard JD. Aerosol bolus dispersion and aerosol-derived airway morphometry: Assessment of lung pathology and response to therapy. Part 1. J Aerosol Med 1996; 9:183–206.
22. Bennett WD, Zeman KL, Kim C. Variability of fine particle deposition in healthy adults: effects of age and gender. Am J Crit Care Med 1996; 153:1641–1647.
23. Zanen P, Go LT, Lammers J-W. Optimal particle size for 132 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996; 51:977–980.
24. Esmailpour N, Hogger P, Rabe K, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997; 10:1496–1499.
25. Ilowile JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolised gentamicin in cystic fibrosis. Am Rev Respir Dis 1987; 136:1445–1449.
26. Newman S. Scintigraphic assessment of therapeutic aerosols. Crit Rev Ther Drug Carrier Syst 1993; 10:65–109.
27. Gonda I. Scintigraphic techniques for measuring in vivo deposition. J Aerosol Med 1996; 9:S59–S67.
28. Chrystyn II. Is total dose more important than particle distribution? Respir Med 1997; 91 (suppl A):17–19.
29. Thompson PJ, Davies RJ, Young WF, Grossman AB, Donnell D. Safety of hydrofluoroalkane- 134a beclomethasone diproprionate extrafine aerosol. Respir Med 1998; 91(suppl A):33–39.
30. Dolovich MB, Sanchis J, Rossman C, Newhouse MT. Aerosol penetration: a sensitive index of peripheral airways obstruction. J Appl Physiol 1976; 40:468–471.
31. Itoh H, Ishii Y, Maeda H, Toso G, Torizuka K, Smalldone G. Clinical observations of aerosol deposition in patients with airways obstruction. Chest 1981; 80(suppl):837–840.
32. Baskin M, Abd A, Ilowite J. Regional deposition of aerosolised pentamidine: effects of body position and breathing pattern. Ann Intern Med 1990; 113:677–683.
33. Smaldone GC. Deposition patterns of nebulised drugs: is the pattern important? J Aerosol Med 1994; 7:S25–S32.
34. Murakam, G., Igarashi T, Adachi Y. Measurement of bronchial hyperactivity in infants and preschool children using a new method. Ann Allergy 1990; 64:383–387.
35. Tal A, Golan H, Aviram M. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J Pediatr 1996; 128:479–484.
36. Iles R, Lister P, Edmunds AT. Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child 1999; 81:163–165.
37. Conway J, Fleming J, Holgate S. Three-dimensional imaging of inhaled aerosols. Eur Respir Rev 1997; 7:44,180–183.
38. Dolovich M, Nahmias C, Coates G. Unleashing the PET: Applying 3D functional imaging to the lung. In: Byron P, Daly R, Farr SJ, eds. Proceedings of Respiratory Drug Delivery VII. Buffalo Grove, IL: Interpharm Press, 2000.
39. Bailey MR, Dorrian M-D, Birchall A. Implications of airway retention for radiation doses from inhaled radionulides. J Aerosol Med 1995; 8:373–390.
40. Everard ML. The use of radiolabelled aerosols for research purposes in paediatric patients: ethical and practical aspects. Thorax 1994; 49:1259–1266.
41. Makrigiorgos GM, Adelstein SJ, Kassis AI. Limitations of conventional internal dosimetry at the cellular level. J Nucl Med 1989; 30:1856–1864.
42. Use of ionizing radiation and radionuclides on human beings for medical research, training and non-medical pruposes. World Health Organization WHO Technical Series Report 611, Geneva 1977.
43. Farr SJ. The physico-chemical basis of radiolabelling metered dose inhalers with 99m TC. J Aerosol Med 1996; 9(suppl 1):S27–S36.
44. Atkins HL, Weber DA, Susskind H, Thomas SR. MIRD dose estimate report No. 16: Radiation absorbed dose from technetium -99m diethylenetriaminepentaacetic acid aerosol. J Nucl Med 1992; 33:1717–1719.
45. Melchor R, Biddiscombe MF, Mak VHM, Short MD, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48:506–511.
46. Fok TF, Monkman S, Dolovich M, Gray S, Coates G, Paes B, Rashid F, Newhouse M, Kirpalani H. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1996; 21:301–309.
47. Devidason S, Everard ML, MacErlean C, Summer Q, Rollo C, Swift P, Borgstrom L, Le Souef PN. Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J 1997; 10:2023–2028.
48. Martonen TB, Yang Y, Dolovich M. Definition of airway composition within gamma camera images. J Thorac Imaging 1993; 9:188–197.
49. Martonen TB, Yang Y, Dolovich M, Guan X. Computer simulations of lung morphologies within planar gamma camera images. Nucl Med Commun 1997; 18:861–869.
50. Chan HK. Use of single photon emission computed tomography in aerosol studies. J Aerosol Med 1993; 6:23–32.
51. Phipps P, Gonda J, Bailey D, Borham P, Bautovich G, Anderson S. Comparison of planar and tomographic gamma scintigraphy to measure the penetration index of inhalation aerosols. Am Rev Respir Dis 1989; 139:1516–1523.
52. Logus JW, Trajan, M Hooper HR, Lentle BC, Mann SFP. Single photon emission tomography of lungs imaged with Tc-labelled aerosol. J Can Assoc Radiol 1984; 35:133–138.
53. Perring S, Summers QA, Fleming JS, Nassim MA, Holgate ST. A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler. Br J Radiol 1994; 67:46–53.
54. Chua HL, Collis GG, Maxwell L, Chan K, Langford JH, Newbury AM, Bower GD, Le Souef PN. The effect of age and method of delivery on aerosol deposition in children Am Rev Respir Dis 1991; 143
55. Fleming JS, Hashish AH, Conway JH, Nassim MA, Holgate ST, Halson P, Moore E, Bailey AG, Martonen TB. Assessment of deposition of inhaled aerosol in the respiratory tract of man using three dimensional multi-modality imaging and mathematical modelling. J Aerosol Med 1996; 9:317–327.
56. Fleming JS, Hashish AH, Conway JH, Hartley-Davis R, Nassim MA, Guy MJ, Coupe J, Holgate ST, Moore E, Bailey AG, Martonen TB. A technique for simulating radionuclide images from the aersool deposition pattern in the airway tree. J Aerosol Med 1997; 10:199–212.
57. Schuster DP. Positron emission tomography: theory and its application to the study of lung disease. Am Rev Resp Med 1989; 139:818–840.
58. Rhodes CG, Hughes JMB. Pulmonary studies using positron emission tomography. Eur Respir J 1995; 8:1001–1017.
59. Dolovich M, Nahmias C, Thompson M, Uki S, Freitag A, Coates G. Positron emission tomographic PET imaging of the lung in cystic fibrosis: 3D assessment of the distribution of inhaled therapy. AJRCCM 1999; 59(part 2):A687.
60. Dolovich M, Inman M, Wahl L, Nahmias C, Hargreave F, Coates G. 3D imaging of the lung: PET scanning and aerosols. Am J Resp Crit Care Med 1998; 157:A78.
61. Alderson PO, Secker-Walker RH, Strominger DB, Markham J, Hill RL. Pulmonary deposition of aerosols in children with cystic fibrosis. J Pediatr 1974; 84:479–484.
62. Thomas SHL, O’Doherty MJ, Graham A, Blower PJ, Geddes DM, Nunan T O. Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers. Thorax 1991a; 46:717–721.
63. Witten ML, Bowers MC, Hall JN, Quan SF, Shen Q, Lemen RJ. A rapid analytical method for measuring drug distribution in aerosols. Radiopharmacy 1992; 20:155–158.
64. O’Doherty MJ, Thomas, S, Page C, Clark AR, Mitchell D, Heduan E, Nunan TO, Bateman NT. Does 99mTc human serum albumin alter the characteristics of nebulised pentamidine isethionate? Nucl Med Commun 1989; 10:523–529.
65. O’Doherty MJ, Thomas SHL, Page CJ, Blower PJ, Bateman NT, Nunan TO. Disposition of nebulized pentamidine measured using direct radiolabel 123 iodopentamidine. Nuc Med Commun 1993; 14:8–11.
66. Svartengren K, Svartengren M, Philipson K, Barck C, Bylin G, Camner P. Clearance in small ciliated airways in allergic asthmatics after bronchial provocation. Respiration 1999; 66:112–118.
67. Cheung D, Bowen B, Rashid F, Rhem R, Dolovich M. Preparation of microaggregated human serum albumin labelled with 99mTc to enable in vivo evaluation of suspension aerosols. Am J Resp Crit Care Med 1998; 157:A638.
68. Newman SP, Pellow PGD, Clarke SW. Droplet size distributions of nebulised aerosols for inhalation therapy. Phys Physiol Meas 1986; 7:139–146.
69. Sanchis J, Dlovich M, Chalmers R, Newhouse MT. Quantitation of regional aerosol clearance in the normal lung. J Appl Physiol 1972; 33:757–762.
70. Alvine GF, Rogers P, Fitzsimmons KM, Ahrens RC. Disposable nebulizers. How reliable are they? Chest 1992; 101:316–319.
71. Watterberg KL, Clark AR, Kelly HW, Murphy S. Delivery of aerosolized medication to intubated babies. Pediatr Pulmonol 1991; 10:136–141.
72. Thomas SHL, O’Doherty MJ, Page CJ, Nunan TO. Variability in the measurement of nebulized aerosol deposition in man. Clin Sci 1991; 81:767–775.
73. Bennett WD. Aerosolized drug delivery: fractional deposition of inhaled particles. J Aerosol Med 1991; 4:223–227.
74. Spiro SG, Singh CA, Tolfree SE, Partridge MR, Short MD. Direct labelling of ipratropium bromide aerosol and its deposition pattern in normal subjects and patients with chronic bronchitis. Thorax 1984; 39:432–435.
75. Newman SP, Millar AB, Lennard-Jones TR, Moren F, Clarke SW. Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax 1984; 39:935–941.
76. Zainudin BMZ, Biddiscombe M, Tolfree SEJ, Short M, Spiro SG. Deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990; 45:469–473.
77. Vidgren P, Vidgren M, Paronen P, Vainio P, Karjalainen P, Nuutinen J. Removal of inhaled 99mTc-labelled particles of disodium cromoglycate from the lungs. Acta Pharm Nord 1991; 3:155–158.
78. Kohler D, Fleischer W, Matthys H. New method for easy labelling of β-agonists in metered dose inhalers with technetium 99m. Respiration 1988; 53:65–73.
79. Summers QA, Clark AR, Hollingworth A, Fleming J, Holgate ST. The preperation of a radiolabelled aerosol of nedocromil sodium for administration by metered dose inhaler that accurately preserves particle size distribution of the drug. Drug Invest 1990; 2:90–98.
80. Newman SP, Clark AR, Talee N, Clarke SW. Pressurised aerosol deposition in the human lung with and without an “open” spacer. Thorax 1989; 44:706–710.
81. Clarke JG, Farr SJ, Wicks SR. Technetium-99m labelling of suspension type pressurised metered dose inhalers comprising various drug/surfactant combinations. Int J Pharm 1992; 80:R1–R5.
82. Vidgren M, Paronen P, Vidgren P, Nuutinen J, Vainio P. Effect of the new spacerdevice on the deposition of the inhaled metered dose aerosol. Pharmazie 1990; 45:922–924.
83. Zainudin BMZ, Biddiscombe M, Tolfree SEJ, Short M, Spiro SG. Comparison of bronchodilator responses and deposition patterns of albutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990; 45:469–473.
84. Newman SP, Moren F, Trofast E, Talee N, Clarke SW. Deposition and clinical effcicacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. Eur Respir J 1989; 2:247–252.
85. Dolovich M. In vitro measurements of delivery of medications from MDIs and spacer devices. Proceedings of in vitro/in vivo standards of measurement for MDIs Workshop, Atlanta GA. J Aerosol Med 1996; 9(suppl 1):S49–S58.
86. Borgström L, Derom E, Stahl E, Wahlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153:1636–1640.
87. Dolovich M, Ruffin R E, Roberts R, Newhouse M. Optimal delivery of aerosol from metered dose inhalers. Chest 1981; 80S:911–915.
88. Everard ML, Devidason S, Le Souef PN. Effect of multiple actuations on total and respirable dose delivered by metered dose inhalers. Thorax 1995; 50:746–749.
89. Newman SP, Pavia D, Garland N, Clarke SW. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis 1982; 63(suppl 119):57–65.
90. Thorsson L, Edsbacker S. Lung deposition froma pressurised metered dosc inhaler attached to a spacer. Eur Respir J 1998; 12:1340–1345.
91. Smaldone GC, Fuhrer J, Steigbigel RT, Mc Peck M. Factors determining pulmonary deposition of aerosolized Pentamidine in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1991; 143:727–737.
92. Gonda I. Absolute and and relative quantification of deposition by scintigraphy. J Biopharm Sci 1992; 3:191–197.
93. Messina MS, Smaldone GC. Evaluation of quantitative aerosol techniques for use in bronchoprovocation studies. J Allergy Clin Immunol 1985; 75:252–257.
94. Cross CE, Hornof WJ, Koblik PD, Fisher PE. Aerosol deposition: practical considerations of methodology for direct measurement of aerosol delivery to the lung bronchiolar-alveolar surfaces. J Aerosol Med 1992; 5:39–45.
95. Fok TF, Al-Essa M, Kirpalani II, Monkman SM, Bowen B, Coates G, Dolovich M. Estimation of pulmonary deposition of aerosol using gamma scintigraphy. J Aerosol Med 1999; 12:9–15.
96. Asmundsson T, Johnson RF, Kilburn KH, Goodrich JK. Efficiency of nebulizers for depositing saline in human lung. Am Rev Respir Dis 1973; 108:506–512.
97. Ruffin RE, Dolovich MB, Wolff RK, Newhouse MT. The effects of preferential deposition of histamine in the human airway. Am Rev Respir Dis 1978; 117:485–492.
98. Pitcairn GR, Newman SP. Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med 1997; 10:187–198.
99. Fleming JS, Conway JH, Holgate ST, Moore EA, Hashish AH, Bailey AG, Martonen TB.: Evaluation of the accuracy and precision of lung aerosol deposition measurements from planar radionulcide imaging using simulation. Phys Med Biol 1998; 43:2423–2429.
100. Macey DJ, Marshall R. Absolute quantification of radiotracer uptake in the lungs using a gamma camera. J Nucl Med 1982; 23:731–735.
101. Forge NI, Mountford PJ, O’Doherty MJ. Quantification of technetium-99m lung radioactivity from planar images. Eur J Nucl Med 1993; 20:10–15.
102. Agnew JE. Characterizing lung aerosol penetration. J Aerosol Med 1991; 3:237–249.
103. Dolovich M, Sanchis J, Rossman C, Newhouse MT. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J Appl Physiol 1976; 40(3):468–471.
104. Bennett WD, Ilowite JS. Dual pathway clearace of 99m Tc-DTPA from the bronchial mucosa. Am Rev Respir Dis 1989; 139:1132–1138.
105. Assessing lung deposition of inhaled medication. Consensus statement from a workshop of the British Association for Lung Research. Respir Med 1999; 93:123–133.
106. Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai T. Hegele RG. Inflammation in small airways in asthma. J Allergy Clin Immunol 1997; 100:44–51.
107. Leach CL, Davidson PJ, Boudreau RJ. Improving airway targeting with the CFCfrec HFA-beclomethasone metered dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12:1346–1353.
108. Richards R, Simpson S, Renwick A, Holgate S. The absorption and distribution kinetics of cromolyn sodium and the influence of inhalation technique. J Pharmacol Exp Ther 1987; 241:1028–1032.
109. Auty RM, Brown K, Neale MG, Snashall PD. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the spinhaler. Br J Dis Chest 1987; 81:371–380.
110. Edsbacker S, Szefler S. Glucocorticoid pharmacokinetics: principles and applications. In: Schleimer RP, Busse WW, O’Byrne P, eds. Inhaled Glucocorticoids in Asthma: Mechanisms and Clinical Actions. New York: Marcel Dekker, 1997:381–445.
111. Pedersen Steffensen G, Ohlsson S. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. Br J Clin Pharmacol 1993; 36:211–214.
112. Thorsson L, Edsbacker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered-dose inhaler. Eur Respir J 1994; 7:1839–1844.
113. Borgstrom L, Newman S, Weisz A, Moren F. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci 1992; 81:753–755.
114. Newman S, Steed K, Hooper G, Kallen A, Borgstrom L. Comparison of gamma scintigraphy and pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurised metered dosc inhaler. Pharm Res 1995; 12:231–266.
115. Beckman O, Bondesson E, Asking L, Kallen A, Borgstrom L. Intra- and interindividual variations in pulmonary deposition via Turbuhaler and pMDI. Drug Delivery to the Lungs VI. The Aerosol Society, 1995.
116. Johnson M. Fluticasone proprionate: pharmacokinetics and pharmacodynamic implications of different aerosol delivery systems. In: Byron PR, Farr SJ, eds. Proceedings of RRD VI. Hilton Head, SC, 1998.
117. Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren J-E. Pharmacokinetics and systemic effects of inhaled fluticasone proprionate in healthy subjects. Br J Clin Pharmacol 1997; 43:155–161.
118. Mollman H, Wagner M, Meibohm B, Hocchaus G, Barth J, Stockman R, Kreig M, Weisser H, Falcoz C. Darendorf H. Pharmacokinetic and pharmacodynamic evaluation of fluticasone proprionate after inhaled administration. J Clin Pharmacol 1998; 53:459–467.
119. Agertoft L, Pedersen S. Systemic availability and pharmcokinetics of nebulised budesonide in pre-school children with asthma. Arch Dis Child 1998; 79:0–6.
120. Derendorf H, Hochhaus G, Rohatagi S, Mollmann H, Barth J, Sourgens H, Erdmann M. Pharmakokinetics of triamcinolone acetonide after intravenous, oral and inhaled administration. 1995; 35:302–305.
121. Falcoz C, Mackie AE, Moss J, Norton J, Ventresca GP, Brown A, Field E, Harding SM, Wire P, Bye A. Pharmacokinetics and systemic exposure of inhaled beclomethasone diproprionate. Eur Respir J 1996; 9(suppl 23):162S.
122. Schmekel B, Borgstrom L, Wollmer P. Differences in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. Thorax 1991; 46:225–228.
123. Schmekel B, Borgstrom L, Wollmer P. Exercise increase the rate of pulmonary absorption of inhaled terbutaline. Chest 1992; 101:742–745.
124. Pauwels R, Newman S, Borgstrom L. Airway deposition and airway effects of anti-asthma drugs delivered from metered-dose inhalers. Eur Respir J 1997; 10:2127–2138.
125. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52:476–482.
126. Hindle M, Newton DAG, Chrystyn H. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax 1993; 48:607–610.
127. Chenge JK, Chrystyn H. Volumatic usage: some generic salbutamol metered dose inhalers can be used. Thorax 1994; 49:1162–1163.
128. Hindle M, Newton DAG, Chrystyn H. Dry powder inhalers are bioequivalent to metered-dose inhalers: a study using a new urinary albuterol (Salbutamol) assay technique. Chest 1995; 107:629–633.
129. Newnham DM, McDevitt DG, Lipworth BJ. Comparison of the extrapulmonary β2-adrenorecptor responses and pharmacokinetics of salbutamol given by standard metered dose inhaler and modified actuator device. Br J Clin Pharmacol 1993; 36:445–450.
130. Newnham DM, Lipworth BJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (Venstream). Thorax 1994; 49:762–770.
131. Clark DJ, Gordon-Smith J, McPhate G, Clark G, Lipworth BJ. Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Thorax 1996; 51:325–326.
132. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996; 42:697–705.
133. Johnson MA, Newman SP, Bloom R, Talaee N, Clarke SW. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Chest 1989; 96:1–10.
134. Derom E, Pauwels R. Relationship between airway deposition and effects for inhaled bronchodilators. In: Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, 1998.
135. Dolovich M. New propellant-free technologies under investigation. J Aerosol Med 1999; (suppl 1):S9–S17.